(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2010 (14.05.2010)

PCT

(10) International Publication Number
WO 2010/052344 A3

(51) International Patent Classification:
C07K 16/22 (2006.01)

(21) International Application Number:
PCT/EP2009/064947

(22) International Filing Date:
10 November 2009 (10.11.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/112,957 10 November 2008 (10.11.2008) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **XU, John** [US/CN]; China Novartis Institutes for, BioMedical Research Co., Ltd., No. 8 Building, Zhangjiang Hi-Tech Park, Pudong New Area Shanghai 201203 (CN). **GAO, Yuan** [CN/CN]; China Novartis Institutes for, BioMedical Research Co., Ltd., No. 8 Building, Zhangjiang Hi-Tech Park, Pudong New Area Shanghai 201203 (CN). **FORNARO, Mara** [IT/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **HILLENBRAND, Rainer** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **LEGAY, Francois** [FR/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **STOELLNER, Daniela** [AT/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH).

(74) Agent: **SPINNER, David**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
28 October 2010

WO 2010/052344 A3

(54) Title: ANTIBODIES TO MODIFIED HUMAN IGF-1/E PEPTIDES

(57) Abstract: High- specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynarnie (PD) assessments of IGF- 1 / E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF- 1/E proteins in samples.